Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDE-01 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Sirius Therapeutics (also known as Sirius Natural) for the treatment of complement disorders. The drug utilizes siRNA-mediated gene silencing technology to target a specific, currently undisclosed, component of the complement system. SRNDE-01 is designed for delivery using Sirius' proprietary delivery platform, which is capable of targeting tissues including the liver, adipose, heart, kidney, or central nervous system (CNS). The program is currently in the preclinical/IND-enabling stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRNDE-01.